Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buntanetap in Mild to Moderate Alzheimer's Disease
NCT05686044Phase 3Completed
- Sponsor
- Annovis Bio, Inc.
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buntanetap in Alzheimer's disease (AD), sponsored by Annovis Bio, Inc.. Started Apr 2023; status: completed.
02
Drugs
buntanetap
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05686044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686044.